Now Approved

These are the latest cancer treatments approved by the FDA.

June 15, 2020 By Liz Highleyman

The COVID-19 pandemic hasn't slowed down the Food and Drug Administration's approval of new cancer treatments. Here are the latest arrivals:

- Jelmyto (mitomycin) for upper urinary tract cancer
- Koselugo (selumetinib) for pediatric neurofibromatosis (nerve tumors)
- Pemazyre (pemigatinib) for cholangiocarcinoma (bile duct cancer)
- Retevmo (selpercatinib) for non-small-cell lung cancer and thyroid cancers
- Sarclisa (isatuximab) for multiple myeloma
- Tabrecta (capmatinib) for non-small-cell lung cancer
- Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer
- Tukysa (tucatinib) for advanced or metastatic HER2-positive breast cancer.

© 2026 Smart + Strong All Rights Reserved.